Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from Leeds Teaching Hospital NHS Trust, Leeds, UK, provides an insight into the use of measurable residual disease (MRD) as an endpoint in clinical trials. MRD allows for comparison of different drug combinations by looking at the level of MRD negativity that is reached. Prof. Hillmen highlights how this should be an objective endpoint in all clinical trials, as generally patients who are MRD negative have longer overall survival and progression-free periods. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

свернуть